Monopar Therapeutics (MNPR) vs Shattuck Labs (STTK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Shattuck Labs (STTK) has outperformed Monopar Therapeutics (MNPR) over the past year, gaining 130.8% versus a loss of 15.0%. Over five years, MNPR leads with a +241.3% price change compared with -70.7% for STTK. Shattuck Labs is the larger company by market cap ($567.6 million vs $562.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNPR | STTK |
|---|---|---|
| Share price | $83.78 | $5.66 |
| Market cap | $562.35M | $567.55M |
| 1-day change | +5.29% | -3.50% |
| YTD return | +28.30% | +54.93% |
| 1-year return | -14.96% | +130.82% |
| 5-year return | +241.26% | -70.74% |
| EPS (TTM) | $-2.20 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $124.82 | $8.33 |
| 52-week low | $50.07 | $1.70 |
| Distance from 52-week high | -32.88% | -32.11% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +55.07% | +169.14% |
| Average volume | 218.50K | 1.20M |
| Shares outstanding | 6.71M | 100.36M |
| Employees | 22 | 40 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STTK has outperformed MNPR by 145.8 percentage points over the past year.
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Healthcare · Biotechnology · 22 employees
About Shattuck Labs
STTK stock →Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
Healthcare · Biotechnology · 40 employees
MNPR vs STTK FAQ
Which is bigger, Monopar Therapeutics or Shattuck Labs?
Shattuck Labs (STTK) is larger, with a market capitalization of $567.55M compared with $562.35M for Monopar Therapeutics (MNPR).
Which stock has performed better over the past year, MNPR or STTK?
STTK returned +130.82% over the past 12 months, compared with -14.96% for MNPR (price return, excluding dividends). Past performance does not predict future results.
Are Monopar Therapeutics and Shattuck Labs in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.